the efficacy and safety of Panax ginseng C.A. Meyer sprout extract on improvement of Memory Function

A 12 weeks, randomized, double-blind, placebo-controlled human trial to evaluate the efficacy and safety of Panax ginseng C.A. Meyer sprout extract on improvement of Memory Function

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0007225

Enrollment

Registered

2022-04-25

Start date

2022-04-28

Completion date

Unknown

Last updated

2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : • Panax ginseng C.A. Meyer sprout extract group: once a day, 2 capsule once, after breakfast, for 12 weeks(700 mg/day, 450 mg/day for Panax ginseng C.A. Meyer sprout extract) •

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Males and females aged 55-75 years at the screening examination 2) Those who complain of subjective memory loss {one or more points in the subjective memory loss questionnaire (SMCQ)} 3) A person whose age and educational background standard deviation have been reduced by more than one of the three items (free recall, delayed recall, and re-insurance test) of the Seoul Language Learning Test (SVLT) or Ray Complex Figure Test (RCFT), which is a memory test 4) Participants who have fully understand the information provided about the study voluntarily decided to participate and agree to comply with precautions.

Exclusion criteria

Exclusion criteria: 1)Patients with a clinically significant disease requiring treatment (i.e., acute or chronic cardiovascular system, endocrine system, immune system, respiratory system, kidney and urinary system, neuropsychiatric system, musculoskeletal inflammation, inflammatory disease, blood and tumor disease, gastrointestinal disease, etc.) 2)Patients with a history of antipsychotic medication use within 3 months prior to the screening examination 3)Patients with a history of clinically significant hypersensitivity reactions to drugs and test products 4)Patients who have participated in other clinical trials within 3 months prior to the screening examination 5)Patients with a Severe score of 29-63 points as a result of the Depression Scale (BDI) test 6)Patients who are judged ineligible to participate in the trial by the principal investigator for other reasons, including laboratory test outcomes

Design outcomes

Primary

Measure	Time frame
Seoul Verbal Learning Test;Rey Complex Figure Test;Korean Version of the Montreal Cognitive Assessment	—

Secondary

Measure	Time frame
Subject Memory Complain Questionnaire;Perceived stress scale;Beck Depression Inventory;Pittsburgh Sleep Quality Index Korean version;Memory-related blood outcome;antioxidant oucome;imflammatory outcome	—

Countries

Korea, Republic of

Contacts

Public ContactSoo jung Park

Woosuk University Korean Medicine Medical Center

taorgi@hanmail.net+82-63-220-8676

Outcome results